Ron Scarboro, Azurity Pharmaceuticals, explains how cross-functional development, disciplined reformulation, and post-approval metrics can help proven medicines work in everyday use.
News|Articles|February 4, 2022
Industry Responds to the UK Gov’s Levelling Up White Paper
Author(s)Pharmaceutical Technology Editors
ABPI has responded to the publication of a white paper on ‘Levelling Up’ by the government of the United Kingdom.
Advertisement
The Association of the British Pharmaceutical Industry (ABPI) has responded to the publication of a white paper on ‘Levelling Up’ by the government of the United Kingdom, in a statement released on Feb. 2, 2022.
The aim of the Levelling Up white paper is to provide details on how the government plans to spread out opportunity more equally within the UK by the year 2030. According to Richard Torbett, chief executive of the ABPI, it is essential that the country’s life sciences’ sector is strong to aid with levelling up.
“The sector is already represented in every region across the UK, but by backing life sciences—and through the creation of highly-skilled, well-paid jobs in science, R&D and manufacturing—there is even greater potential for the life sciences to help level up the UK,” Torbett said in the press release. “The commitment to close the healthy life expectancy gap by 2030 is particularly important. To close this gap and transform the lives of patients, we need to make sure that people can access the best possible care wherever they live in the UK. Getting this right must be central to the missions set out today.”
Source:
Advertisement
Related to this article
The FDA approves oral pritelivir for drug-resistant herpes sores in immunocompromised patients; what it means for antiviral development and manufacturing.
This week, drug formulation and manufacturing experts showcased their knowledge, and companies exhibited their products, at CPHI Milan.
FDA approves Teva’s Weltruza, a once-monthly subcutaneous olanzapine for schizophrenia whose copolymer depot eliminates post-injection monitoring.
Equivalence test using two one-sided tests are widely used for demonstrating the comparability of treatment effects in different research fields. The method described in the manuscript aims to use simulations in Microsoft Excel to compute power for 2 one-sided tests for two groups with unequal variances.
Richard Jaenisch examines whether FDA's NAM pathway truly shortens drug pipelines or just shifts the evidentiary burden elsewhere.
Susan J. Schniepp, distinguished fellow with Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical, with Parexel, clear up some of the confusion about what does and does not need to be complied with regarding standards set by international pharmacopoeias.
Mitigating nitrosamine risk requires assessing each product individually, says Bram Baert, Global Head of Regulatory Affairs at Capsugel, and Sandrine Picco, Senior Analytical Specialist on Capsugel's Innovaform Accelerator Team, in this interview with PharmTech.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Pritelivir Shifts Resistant Herpes Care from Intravenous to Oral
2
Manufacturing Intelligence: Organoids, Organ-on-a-Chip, and the Trust Gap
3
Complying with International Pharmacopoeias
4
CPHI Milan 2026: Nitrosamine Risk Mitigation, Part 2
5